Phathom Pharmaceuticals Inc.
NASDAQ · PHAT·Florham Park, NJ·Small-cap·Approved
GI-focused biopharma commercializing VOQUEZNA (vonoprazan), a potassium-competitive acid blocker approved for erosive GERD, non-erosive GERD heartburn, and H. pylori eradication. Guiding $320-345M in 2026 revenue with a path toward operating profitability.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Phathom Pharmaceuticals Corporate Overview April 2026 | Corporate overview | April 1, 2026 | 37 |